One of the proposed repositioning candidates for LS was dasatinib, a BCR-ABL inhibitor, that was originally designed for treating chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.